The Top 5 Analyst Questions From Privia Health’s Q2 Earnings Call
Privia Health’s second quarter results were met with a negative market reaction as investors digested the company’s strong revenue growth alongside a material shortfall in non-GAAP profit relative to Wall Street expectations. Management attributed the top-line performance to robust provider signings and expanded value-based attributed lives, noting that implemented provider growth of 10.1% and value-based attributed lives growth of 19.2% drove overall practice collections. CEO Parth Mehrotra pointed to “strong new provider signings across all our markets,” while CFO David Mountcastle highlighted operational leverage and ongoing investments.
Is now the time to buy PRVA? Find out in our full research report (it’s free).
Privia Health (PRVA) Q2 CY2026 Highlights:
Revenue: $632.6 million vs analyst estimates of $597.2 million (21.4% year-on-year growth, 5.9% beat)
Adjusted EPS: $0.19 vs analyst expectations of $0.24 (22.2% miss)
Adjusted EBITDA: $37.43 million vs analyst estimates of $36.88 million (5.9% margin, 1.5% beat)
Operating Margin: 1.9%, up from 0.6% in the same quarter last year
Sales Volumes rose 10.1% year on year (13.8% in the same quarter last year)
Market Capitalization: $2.75 billion
While we enjoy listening to the management’s commentary, our favorite part of earnings calls is the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.
Our Top 5 Analyst Questions From Privia Health’s Q2 Earnings Call
Elizabeth Anderson (Evercore ISI) asked about the risk of delayed CMS shared savings payments and how investors should monitor for updates. CEO Parth Mehrotra indicated there was little concern, citing historical reliability and describing any delay as a matter of timing, not risk.
Matthew Mardula (William Blair) queried why management is confident in reaching the high end of its long-term EBITDA margin target. CFO David Mountcastle pointed to operational leverage, AI initiatives, and the maturity of existing markets as drivers, but offered no firm timeline.
Daniel Grosslight (Citi) pressed on the apparent deceleration in second-half practice collections growth. Mehrotra responded that the guidance is “prudent” rather than reflecting specific headwinds, and that ambulatory utilization trends remain favorable.
A.J. Rice (UBS) requested more detail on AI use cases. Mehrotra emphasized deployment across corporate and care workflows, including billing, clinical decision support, and patient experience, all aimed at compressing costs and supporting margin expansion.
Ryan Langston (TD Cowen) asked about the integration and performance of the Evolent and IMS acquisitions. Mehrotra described both as progressing well and contributing to updated guidance, with Arizona highlighted as a target for further expansion.
Story Continues